Dufine

Quick links to important sections

Dufine

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dufine

Quick Facts

Property Description
Active ingredient Clomifene Citrate
Form Oral tablet
Pharmacological class Selective Estrogen Receptor Modulator (SERM)
Common use Ovulation Induction
Origin Synthetic, nonsteroidal compound

Dufine: Defining the Drug Entity and Its Composition

Dufine is a single-ingredient, prescription-only medicinal product supplied as an oral tablet used in reproductive medicine. Its active substance is Clomifene Citrate, which is chemically defined as a synthetic, nonsteroidal compound and a triphenylethylene derivative. This formulation is designed for systemic delivery, ensuring the active substance is absorbed to reach the central endocrine system after oral ingestion. Clomifene is classified as an ovulatory stimulant and an estrogen agonist/antagonist.

What Type of Medicine is Clomifene (Dufine)?

Clomifene is pharmacologically categorized as a Selective Estrogen Receptor Modulator (SERM). This classification is based on the compound’s ability to interact with estrogen receptors in a tissue-selective manner, exhibiting mixed agonist and antagonist activity. This designation highlights that the drug modulates estrogenic pathways without acting as a simple hormone replacement agent. Clomifene is clinically recognized for the management of infertility and is categorized among sex hormones and their antagonists.

General Purpose of Dufine as a Fertility Agent

The general purpose of Dufine is to act as an ovulatory stimulant to address issues related to absent or irregular ovulation. By selectively binding to central estrogen receptors, the drug promotes the increased secretion of the pituitary gonadotropins, specifically Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH). This induced hormonal cascade is intended to stimulate the development and maturation of ovarian follicles, ultimately leading to the necessary surge that triggers ovulation. Dufine is typically used in scenarios where the individual is experiencing anovulatory infertility, aiming to restore a normal, predictable reproductive cycle.

What side effects are possible with Dufine?

Possible Side Effects and Safety Information

The safety profile of Dufine (Clomifene Citrate) is officially structured by the frequency and physiological system of the documented adverse reactions. Information on possible effects is derived strictly from government regulatory documentation, such as official prescribing information.

Frequency and System-Organ Classifications

Adverse reactions are classified by frequency as observed in clinical data. Very Common ( >10%) reactions include vasomotor flushing (hot flashes) and ovarian enlargement. Common (1% to 10%) effects typically involve headache, nausea/vomiting, abdominal discomfort, and blurred vision. Reactions are documented across multiple System-Organ Classes, primarily affecting the Reproductive System and Breast, the Nervous System, the Gastrointestinal System, and Eye Disorders.

Serious Adverse Reactions and Duration-Related Risks

Regulatory sources explicitly document the potential for serious adverse reactions. These include Severe Ovarian Hyperstimulation Syndrome (OHSS), thromboembolic events (such as pulmonary embolism), and potentially irreversible visual disturbances. Safety documentation links the incidence of visual symptoms and the rare, but possible, risk of a borderline or invasive ovarian tumor to the total cumulative dose or prolonged use, necessitating a strict limitation on the total number of treatment cycles.

Safety Constraints and Special Populations

Use of the medicine is subject to specific safety constraints. Dufine is generally contraindicated in patients with a history of liver disease or undiagnosed abnormal uterine bleeding. Caution is required in patients with pre-existing conditions such as uterine fibroids or certain types of ovarian cysts (those not due to Polycystic Ovary Syndrome), as the medicine has the potential to cause further enlargement.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Clomifene Citrate (Dufine) outlines specific manifestations observed in cases of overdose and provides strict guidance on securing immediate medical care. No mechanisms of action, dosing instructions, or routine safety information are included in this summary.

Documented Overdose Profile

Domain Official Regulatory Statements
Documented Overdose Presentations Nausea, vomiting, vasomotor flushes, abdominal distension, pelvic/abdominal pain, and visual disturbances, including visual blurring, scintillating scotomata, and blind spots [FDA Labeling].
Physiological Systems Affected Gastrointestinal system, vasomotor system, sensory system (vision), and the reproductive system (reversible ovarian enlargement) [FDA Labeling].
Dose-Related Factors Visual disturbances may be prolonged and potentially irreversible, with the risk increasing alongside the total dosage or duration of therapy [FDA Monograph].

Emergency Response and Treatment

Classification Official Regulatory Statements
Severity Classification Severe or life-threatening scenarios may involve Ovarian Hyperstimulation Syndrome (OHSS), associated with complications such as pulmonary edema and thromboembolism [Health Canada Monograph].
Immediate Help Required Individuals must seek emergency medical attention or immediately contact the Poison Help line [NIH MedlinePlus]. Emergency services must be called if the individual is unconscious, experiencing seizures, or has trouble breathing [NIH MedlinePlus].
Overdose-Context Constraints Treatment is strictly limited to symptomatic and supportive measures, including gastrointestinal decontamination; no specific antidote is known [StatPearls/NIH].

This structure reflects how regulatory bodies define the overdose profile by listing specific symptoms and identifying the most serious complication, OHSS. The lack of a specific antidote dictates that the only required action is to secure immediate emergency medical assistance for necessary supportive care and monitoring.

Therapeutic Uses of Dufine

What Dufine treats: main uses and benefits

Dufine is an oral medication primarily used to address certain types of female infertility. It belongs to a class of drugs known as selective estrogen receptor modulators (SERMs). Its therapeutic goal is to induce ovulation in women who do not ovulate spontaneously or who have irregular ovulatory cycles.

Primary Indications

The medication is indicated for women diagnosed with ovulatory dysfunction. This includes several clinical scenarios where the ovaries do not regularly release an egg, which is a prerequisite for natural conception:

  • Anovulation: A condition where the ovaries do not release an egg during a menstrual cycle.
  • Oligo-ovulation: A condition characterized by infrequent or irregular ovulation.
  • Polycystic Ovary Syndrome (PCOS): Dufine is frequently used as a first-line treatment for infertility in patients with PCOS, a common endocrine disorder that often disrupts the normal ovulatory process.

Mechanism of Action and Benefits

The benefit of Dufine lies in its ability to stimulate the body's natural hormonal signaling. It works by interacting with estrogen receptors in the brain, specifically in the hypothalamus and pituitary gland.

Because the medication blocks the negative feedback of estrogen, the brain perceives a low estrogen level. In response, it increases the production of two key hormones:

  1. Follicle-Stimulating Hormone (FSH): This hormone stimulates the growth and maturation of ovarian follicles (the sacs containing the eggs).
  2. Luteinizing Hormone (LH): An increase in LH eventually triggers the release of a mature egg from the ovary.

Clinical Goals

The primary objective of treatment is to achieve a predictable ovulatory response, thereby increasing the probability of conception. By correcting hormonal imbalances that prevent egg release, the medication provides a window of opportunity for fertilization to occur. It is generally most effective in women who have a functional hypothalamic-pituitary-ovarian axis and sufficient endogenous estrogen levels.

Eligibility and Restrictions for Use

Who Can and Cannot Use Dufine?

The official eligibility profile for Dufine (Clomifene Citrate) is strictly defined by regulatory documents, limiting its use to a specific adult population.


Eligible Population

Use is indicated only for adult women with ovulatory dysfunction (anovulation or oligo-ovulation) who are seeking pregnancy. The medicine is not established or indicated for pediatric or geriatric populations.


Absolute Contraindications (Must Not Use)

Official labeling strictly contraindicates Dufine use in the following populations:

  • Patients who are currently pregnant.
  • Individuals with active liver disease or a history of liver dysfunction.
  • Patients with undetermined abnormal uterine bleeding.
  • Those with ovarian enlargement or cysts not due to Polycystic Ovary Syndrome (PCOS).
  • Patients with an organic intracranial lesion (e.g., pituitary tumor) or uncontrolled thyroid or adrenal dysfunction.

Restrictions and Limitations

The medicine is stated to be ineffective and not indicated for patients whose ovulatory failure is due to primary pituitary or primary ovarian dysfunction. Caution is advised for patients with uterine fibroids due to the potential for enlargement, and long-term use beyond six total cycles is not recommended in official guidance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Clomifene Citrate (Dufine) primarily defines interaction constraints based on pharmacodynamic risk and metabolic considerations, rather than extensive pharmacokinetic drug-drug interactions.

Interaction Type Interacting Substance / Condition Official Restriction or Outcome
Pharmacodynamic Gonadotropins (e.g., other ovulation-inducing agents) Associated with an increased risk of Ovarian Hyperstimulation Syndrome (OHSS) due to an additive effect.
Drug-Substance Food or Drinks (non-alcoholic) No known interactions are formally documented with routine food or drinks.
Metabolic Risk Hyperlipidemia (pre-existing or family history) Risk of hypertriglyceridemia is associated with use; periodic monitoring of plasma triglycerides may be indicated.

The US prescribing information and similar regulatory documents do not contain an explicit list of specific CYP-mediated or drug transporter-mediated interactions with other prescription medicines, which is the official context of the drug's interaction profile. Consequently, there are no formally documented mandatory timing separation rules for co-administered substances. This profile strictly reflects the information found in government regulatory documents regarding interaction patterns and constraints.

Mechanism of Action

Dufine, which contains clomiphene citrate, functions as a Selective Estrogen Receptor Modulator (SERM). Its principal biological target is the estrogen receptor (ER), primarily within the hypothalamus and the pituitary gland.

Clomiphene acts as an ER antagonist in the hypothalamus, competitively binding to the receptors and delaying their replenishment. This prolonged occupancy prevents the binding of endogenous estrogen, effectively blocking the normal negative feedback signal exerted by circulating estradiol on the hypothalamic-pituitary-gonadal (HPG) axis.

This disruption of the negative feedback loop leads to an increase in the pulsatile secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus. The elevated GnRH then stimulates the anterior pituitary gland, initiating a downstream cascade that increases the synthesis and release of pituitary gonadotropins: luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The resulting system-level physiological consequence is the modulation of the HPG axis, increasing the circulating concentrations of these key reproductive hormones.

Dosage and Administration Information

How to Use Dufine (Clomifene Citrate): Administration Guidelines

Dufine (Clomifene Citrate) is a prescription-only medication formulated as an oral tablet and is administered exclusively by mouth. The use of this medicine is characterized by a specific cyclic dosing regimen and requires supervision by a physician experienced in gynecologic or endocrine disorders.


Dosing and Schedule

Parameter Administration Principle
Route and Form Oral tablet, typically 50 mg strength
Initial Course 50 mg once daily for 5 consecutive days
Second Course May be increased to 100 mg once daily for 5 days if ovulation does not occur after the initial course.
Treatment Timing Begins on or about the fifth day of the menstrual cycle.

Procedural Context and Limits

The administration of Dufine adheres to a defined protocol. The decision to increase the dose to 100 mg is strictly conditional on the absence of ovulation during the preceding 50 mg course, and the maximum recommended dosage or duration should not exceed 100 mg per day for five days. Treatment is not recommended to be started if a patient has abnormal liver function.

Before initiating the first course and each subsequent course, a pelvic examination is performed to exclude conditions such as pregnancy or ovarian enlargement. Long-term cyclic therapy is generally not advised, with use typically limited to a total of approximately six cycles, even if ovulation is successfully achieved earlier.

Recent Clinical Evidence

Dufine: Recent Clinical Evidence

Primary Indication: Anovulatory Infertility

Clinical research has extensively evaluated Dufine (clomiphene citrate) as a treatment for anovulatory infertility in women seeking pregnancy. The primary mechanism explored in studies involves the induction of ovulation through effects on the hypothalamic-pituitary-ovarian axis. Studies reported that when administered to appropriately selected women with anovulation, clomiphene citrate was associated with ovulation rates that often exceeded 70% in treated cycles.

Efficacy is generally measured by two key outcomes: ovulation rate and subsequent pregnancy rate. While high ovulation rates were reported in many studies, the cumulative pregnancy rate per treated cycle tended to be lower. Factors such as patient age, underlying cause of anovulation, and duration of infertility influenced the reported outcomes.


Comparison with Other Treatments

Comparative trials have also been conducted to explore the use of clomiphene citrate against other fertility interventions. Research examined whether treatment with clomiphene citrate alone yielded comparable live birth rates to gonadotropin therapy or the use of aromatase inhibitors. Findings were often varied, suggesting that the optimal first-line therapy may depend on individual patient profiles. For example, some studies explored whether aromatase inhibitors were associated with a lower risk of multiple births compared to clomiphene citrate in specific populations.


Safety and Tolerability

Safety data collected across multiple clinical trials indicated that clomiphene citrate is generally well-characterized. The most commonly reported side effects included vasomotor symptoms (hot flashes), ovarian enlargement, and gastrointestinal disturbances. A major focus of safety surveillance remains the monitoring of ovarian hyperstimulation syndrome (OHSS), which, while uncommon at standard therapeutic doses, is a potential risk that was observed in some treated patients. The risk of multiple gestation (twins, triplets, etc.) was also consistently reported to be higher in treated cycles compared to natural conception.

Key Studies & References

  1. Effect of clomiphene citrate and metformin combination therapy on clinical pregnancy rate in clomiphene-resistant infertile women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials
  2. Guideline: Management of Infertility in Women
  3. Oral Agents for the Induction of Ovulation: A Comparative Review of Clomiphene Citrate, Letrozole, and Metformin

Frequently Asked Questions (FAQ)

Common questions about Dufine (FAQ)


Q: Can Dufine affect mood or cause emotional changes?

Official regulatory documents list nervous system effects among the documented adverse reactions. These reported effects include experiences such as mood swings and irritability.


Q: Is it normal to feel bloated or heavy while taking Dufine?

Abdominal discomfort, which users may describe as bloating, is a documented common side effect. Ovarian enlargement is also a common adverse reaction, which can contribute to a feeling of fullness.


Q: Is it true that Dufine can sometimes cause vision changes?

Visual symptoms, such as blurred vision, are documented as a side effect. Official product information also notes that potentially irreversible visual disturbances are a possible, although rare, serious adverse reaction.


Q: Do I need any special monitoring or blood tests while on Dufine?

A pelvic examination is listed in regulatory guidance as a requirement before each course of treatment. Additionally, in some patients with a pre-existing or family history of high blood fats, the monitoring of plasma triglyceride levels may be indicated.


Q: Can Dufine cause headaches?

Regulatory safety profiles classify headache as a documented common side effect.


Q: How does Dufine affect the chances of having twins or multiples?

Studies and official information indicate that the possibility of a multiple gestation (such as twins or triplets) is a known potential outcome in treated cycles compared to natural conception.


Q: Is Dufine known to cause stomach upset?

Gastrointestinal effects are documented as common side effects. These include experiences such as nausea, vomiting, and general abdominal discomfort.


Q: What is the general success rate described in official studies for Dufine?

According to clinical studies, ovulation rates were reported in approximately 70% of appropriately selected patients. The subsequent cumulative pregnancy rate among those treated was reported to be lower than the ovulation rate.


Q: Is it normal to experience tenderness in the pelvic area while taking Dufine?

Pelvic discomfort or tenderness is documented in the safety profile. Ovarian enlargement is also listed as a common adverse reaction, which can be related to these feelings in the pelvic region.


Q: How quickly does Dufine start working after you take it?

Ovulation is generally anticipated within 5 to 10 days following the completion of the 5-day course, according to regulatory monitoring information.


Q: Can men take Dufine for any reason?

According to regulatory labeling, the medicine is only indicated and approved for use in women with ovulatory dysfunction who are seeking pregnancy. Use in other populations is not supported by the official indication.


Q: What happens if I miss a day of my Dufine treatment?

Official patient instructions advise against taking two doses at once to make up for the missed one. The guidance also states that medical advice should be consulted.


Q: How soon after stopping Dufine does it leave the body?

The active substance in the medicine is eliminated slowly. Official pharmacokinetic studies show that a component of the medicine has been detected in the body for up to six weeks following the last administration.


Q: Is there any restriction on driving or operating machinery while taking Dufine?

Official warnings state that visual side effects are possible with this medicine. Because of this potential for visual symptoms, activities such as driving a car or operating machinery may be more hazardous than usual.


Q: Why is Dufine only available with a prescription?

It is a prescription drug because its use requires physician supervision, specialized monitoring, and management due to the potential for serious adverse reactions.


Q: Are there different strengths of Dufine, and why would someone use one over another?

The medicine is generally available in 50 mg tablets. The dosage is based on a specific protocol where the initial course uses the 50 mg strength. The dosage may be conditionally increased to 100 mg if the initial course does not result in ovulation.


Q: What if I take too much Dufine by accident?

Taking more than the prescribed amount can raise the risk of serious side effects, including Ovarian Hyperstimulation Syndrome (OHSS). In this scenario, official product information advises seeking immediate medical guidance.


Q: Does Dufine have an official classification, like an antagonist or agonist?

Yes, the medicine is officially categorized in regulatory and pharmacological documents as a Selective Estrogen Receptor Modulator (SERM). This classification describes its ability to interact with estrogen receptors.


Q: Why do some people report feeling lightheaded after taking Dufine?

Dizziness is a documented common side effect of the medicine. Lightheadedness is a term commonly used to describe this type of symptom.


Q: What are the reasons someone might have to stop taking Dufine?

Reasons for discontinuation include the development of any unusual visual symptoms, diagnosis of pregnancy, or reaching the advised limit of six total cycles.


Q: Is Dufine considered safe for people with a history of blood clots?

Serious adverse reactions that have been documented include thromboembolic events (blood clots). This is a major safety consideration documented in the product information.


Q: Can Dufine be used by people who have certain kidney conditions?

Official regulatory documents for the medicine list contraindications related to liver disease, abnormal uterine bleeding, and ovarian cysts. Kidney conditions are not listed as a specific contraindication for use.

How should Dufine be stored and disposed of?

Dufine (Clomiphene Citrate) must be stored under specific conditions to maintain its stability, as mandated by regulatory labeling.


Storage Conditions

Temperature and Environment: The tablets require Controlled Room Temperature, typically between 15 C and 30 C (59 F and 86 F). The medicine must be stored protected from light, moisture, and excessive heat. Storage in damp areas like a bathroom is prohibited.

Container and Safety: Keep the medication in the original container, which must be kept tightly closed. It is mandatory to store the medicine out of the sight and reach of children.


Disposal Instructions

Expired or unused Dufine must be discarded in accordance with local/regional regulations for pharmaceutical waste. Do not release the substance into the environment by flushing it down a toilet or discarding it in household trash, unless instructed otherwise by a local take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dufine found in:

A-Z Index: